Israel Cancer Research Fund

(Learn how and when to remove this message)

The Israel Cancer Research Fund (ICRF) a cancer research fund founded in 1975 by a group of American and Canadian physicians, scientists, and laypeople. The ICRF was founded to prevent the permanent loss of Israel's cancer researchers to foreign universities due to the lack of funding in Israel for newly minted Ph. D.s, post-doctoral fellows and accomplished young scientists (a phenomenon known to many as Israel's "brain drain"). With chapters in New York, Los Angeles, Chicago, Toronto, Montreal, and Jerusalem, ICRF annually sponsors a grant review process conducted by an expert panel of U.S. and Canadian scientists and oncologists and modeled on the NIH grant-making process.

Awards are granted directly to Israeli cancer researchers at all the leading academic and biomedical research centers throughout Israel[citation needed]. To date, the ICRF has funded more than $87 million in awards to Israeli cancer researchers via more than 2,700 fellowships, project grants, career development awards, and professorships.[1] Grants have been provided to over 20 institutions including all major hospitals, universities, and cancer research projects throughout Israel. Breakthrough discoveries by ICRF-funded scientists have led to the development of Gleevec -used in the successful treatment of chronic myelogenous leukemia[citation needed]; Doxil - used in the treatment of breast & ovarian cancer as well as AIDS[citation needed]; p53 – a key tumor suppressor; RAD 51 which identifies the likelihood of breast cancer occurring in women who carry the BRCA 2 gene and Velcade[citation needed]. The basic research ICRF funds have led to treatments and drugs that are benefiting cancer patients around the world.

Awards

See also

References

  1. ^ "Israel Cancer Research Fund". Israel Cancer Research Fund. Retrieved August 10, 2023.

External links

Authority control databases Edit this at Wikidata
International
  • ISNI
  • VIAF
National
  • United States